Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386469718> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W4386469718 abstract "<div><p>Attaining undetectable minimal residual disease (MRD) is the current therapeutic goal for multiple myeloma. But there is a current lack of data regarding the clinical benefit of autologous stem cell transplantation (ASCT) for patients with myeloma achieving early MRD-negative status after induction treatment, in addition to the interaction of longitudinal MRD status with ASCT. The current study included 407 patients with transplant-eligible multiple myeloma with available MRD status from the National Longitudinal Cohort of Hematological Diseases in China (NCT04645199), of whom 147 (34.4%) achieved early undetectable MRD and 182 (44.7%) received ASCT. Early MRD-negative status was associated with a lower risk of disease progression [HR = 0.447; 95% confidence interval (CI), 0.333–0.600; <i>P</i> < 0.001] and death (HR = 0.473; 95% CI, 0.320–0.700; <i>P</i> < 0.001). Of note, patients who achieved undetectable MRD early still benefitted from ASCT, with a remarkable improvement in the median MRD-negative duration (33.5–58.0 months, <i>P</i> < 0.001), progression-free survival (PFS; 46.0–88.3 months, <i>P</i> < 0.001), and overall survival (OS; 76.4 months to not reached, <i>P</i> = 0.003). These clinical benefits were more pronounced in patients with aggressive features (high-risk cytogenetic abnormalities or high tumor burden) compared with standard-risk patients. Similar results were observed in patients with detectable MRD after induction treatment. In addition, we identified four MRD-status transformation patterns following ASCT, which were strongly correlated with diverse survival outcomes (<i>P</i> < 0.001). Our study revealed the enhanced clinical significance of ASCT in patients with transplant-eligible myeloma, regardless of early MRD status, particularly for high-risk patients. Subsequent prospective trials are essential to validate these observations.</p>Significance:<p>Achieving and maintaining undetectable MRD is the current treatment goal for multiple myeloma. Our results emphasized the remarkable clinical benefit of ASCT on MRD-negative duration, PFS, and OS in patients with multiple myeloma regardless of early MRD status. These favorable impacts were more evident in patients with aggressive features. Importantly, dynamic MRD monitoring among ASCT could facilitate personalized stratification of therapeutic approaches.</p></div>" @default.
- W4386469718 created "2023-09-07" @default.
- W4386469718 creator A5002960038 @default.
- W4386469718 creator A5008198016 @default.
- W4386469718 creator A5017214725 @default.
- W4386469718 creator A5017804632 @default.
- W4386469718 creator A5025448721 @default.
- W4386469718 creator A5027278571 @default.
- W4386469718 creator A5028607074 @default.
- W4386469718 creator A5030715375 @default.
- W4386469718 creator A5032464400 @default.
- W4386469718 creator A5040240493 @default.
- W4386469718 creator A5046029756 @default.
- W4386469718 creator A5068633086 @default.
- W4386469718 creator A5072120451 @default.
- W4386469718 creator A5074352094 @default.
- W4386469718 creator A5074372967 @default.
- W4386469718 creator A5083334234 @default.
- W4386469718 date "2023-09-06" @default.
- W4386469718 modified "2023-10-17" @default.
- W4386469718 title "Data from Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment" @default.
- W4386469718 doi "https://doi.org/10.1158/2767-9764.c.6790341.v2" @default.
- W4386469718 hasPublicationYear "2023" @default.
- W4386469718 type Work @default.
- W4386469718 citedByCount "0" @default.
- W4386469718 crossrefType "posted-content" @default.
- W4386469718 hasAuthorship W4386469718A5002960038 @default.
- W4386469718 hasAuthorship W4386469718A5008198016 @default.
- W4386469718 hasAuthorship W4386469718A5017214725 @default.
- W4386469718 hasAuthorship W4386469718A5017804632 @default.
- W4386469718 hasAuthorship W4386469718A5025448721 @default.
- W4386469718 hasAuthorship W4386469718A5027278571 @default.
- W4386469718 hasAuthorship W4386469718A5028607074 @default.
- W4386469718 hasAuthorship W4386469718A5030715375 @default.
- W4386469718 hasAuthorship W4386469718A5032464400 @default.
- W4386469718 hasAuthorship W4386469718A5040240493 @default.
- W4386469718 hasAuthorship W4386469718A5046029756 @default.
- W4386469718 hasAuthorship W4386469718A5068633086 @default.
- W4386469718 hasAuthorship W4386469718A5072120451 @default.
- W4386469718 hasAuthorship W4386469718A5074352094 @default.
- W4386469718 hasAuthorship W4386469718A5074372967 @default.
- W4386469718 hasAuthorship W4386469718A5083334234 @default.
- W4386469718 hasConcept C126322002 @default.
- W4386469718 hasConcept C141071460 @default.
- W4386469718 hasConcept C143998085 @default.
- W4386469718 hasConcept C2776364478 @default.
- W4386469718 hasConcept C2779050716 @default.
- W4386469718 hasConcept C2779823535 @default.
- W4386469718 hasConcept C2780007613 @default.
- W4386469718 hasConcept C2911091166 @default.
- W4386469718 hasConcept C44249647 @default.
- W4386469718 hasConcept C71924100 @default.
- W4386469718 hasConcept C90924648 @default.
- W4386469718 hasConceptScore W4386469718C126322002 @default.
- W4386469718 hasConceptScore W4386469718C141071460 @default.
- W4386469718 hasConceptScore W4386469718C143998085 @default.
- W4386469718 hasConceptScore W4386469718C2776364478 @default.
- W4386469718 hasConceptScore W4386469718C2779050716 @default.
- W4386469718 hasConceptScore W4386469718C2779823535 @default.
- W4386469718 hasConceptScore W4386469718C2780007613 @default.
- W4386469718 hasConceptScore W4386469718C2911091166 @default.
- W4386469718 hasConceptScore W4386469718C44249647 @default.
- W4386469718 hasConceptScore W4386469718C71924100 @default.
- W4386469718 hasConceptScore W4386469718C90924648 @default.
- W4386469718 hasLocation W43864697181 @default.
- W4386469718 hasOpenAccess W4386469718 @default.
- W4386469718 hasPrimaryLocation W43864697181 @default.
- W4386469718 hasRelatedWork W1818467446 @default.
- W4386469718 hasRelatedWork W2521738172 @default.
- W4386469718 hasRelatedWork W2582431155 @default.
- W4386469718 hasRelatedWork W2980534218 @default.
- W4386469718 hasRelatedWork W2981308154 @default.
- W4386469718 hasRelatedWork W3004485101 @default.
- W4386469718 hasRelatedWork W4242486230 @default.
- W4386469718 hasRelatedWork W4385839054 @default.
- W4386469718 hasRelatedWork W4385839235 @default.
- W4386469718 hasRelatedWork W4385839356 @default.
- W4386469718 isParatext "false" @default.
- W4386469718 isRetracted "false" @default.
- W4386469718 workType "article" @default.